anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A compound for polymeric targeted gene delivery carrier consisting of polyethylene glycol (PEG) grafted poly(L-lysine) (PLL) and a targeting moiety (TM), wherein at least one free amino function of the PLL is substituted with said PEG, at least one free amino function of the PLL is substituted with the TM, and the grafted PLL contains at least 50 % unsubstituted free amino function groups. TM is preferably lactose or galactose which are capable of specifically targeting a hepatoma cell or a liver cell. The new synthetic carriers with various substitution ratios of TM-PEG were characterized using NMR spectroscopy. The new polymeric gene carriers of this invention are capable of forming stable and soluble complexes with nucleic acids, which in turn are able to efficiently transform cells. PEG attached to the PLL gives better solubility properties to the gene/carrier complex and improved transfection efficiency without considerable cytotoxicity. Methods of preparing and using the TM-PEG-PLL as polymeric gene carriers to efficiently transfect cells are disclosed.
Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
BACKGROUND: The risk for recurrence in patients with distal gastric cancer can be reduced by surgical radicality. However, dispute exists about the value of the proposed minimum proximal margin distance (PMD). Here, we assess the prognostic value of the safety distance between the proximal resection margin and the tumor.
PATIENTS AND METHODS: This is a single-center cohort study of patients undergoing distal gastrectomy for gastric adenocarcinoma (2001-2021). Cohorts were defined by adequacy of the PMD according to the European Society for Medical Oncology (ESMO) guidelines (≥ 5 cm for intestinal and ≥ 8 cm for diffuse Laurén's subtypes). Overall survival (OS) and time to progression (TTP) were assessed by log-rank and multivariable Cox-regression analyses.
RESULTS: Of 176 patients, 70 (39.8%) had a sufficient PMD. An adequate PMD was associated with cancer of the intestinal subtype (67% vs. 45%, p = 0.010). Estimated 5-year survival was 63% [95% confidence interval (CI) 51-78] and 62% (95% CI 53-73) for adequate and inadequate PMD, respectively. Overall, an adequate PMD was not prognostic for OS (HR 0.81, 95% CI 0.48-1.38) in the multivariable analysis. However, in patients with diffuse subtype, an adequate PMD was associated with improved oncological outcomes (median OS not reached versus 131 months, p = 0.038, median TTP not reached versus 88.0 months, p = 0.003).
CONCLUSION: Patients with diffuse gastric cancer are at greater risk to undergo resection with an inadequate PMD, which in those patients is associated with worse oncological outcomes. For the intestinal subtype, there was no prognostic association with PMD, indicating that a distal gastrectomy with partial preservation of the gastric function may also be feasible in the setting where an extensive PMD is not achievable.
FIELD: medicine, surgery. SUBSTANCE: method includes percutaneous drainage of echinococcous cyst under control of ultrasonic examination by needle-catheter through liver parenchyma. Germicide is used in form of aqueous solution of 30-86% glycerine with 10% solution of Demerol. Exposure takes 3-10 min. Aspirating channel is widened by bougies. Then, microscopic control of cyst contents is made for presence and viability of echinococcus germinal elements. Introduced through widened channel is extirpation device. Then, chitin membrane is removed from cyst. Thin drainage is left for closing residual cavity. EFFECT: reduced operation injury.
PURPOSE:A cosmetic having protecting actin on ultraviolet rays and improved healthy beautifying action on the skin, obtained by blending a cosmetic base with a hot water extracted solution of the bulb of a cluster-amaryllis of amaryllidaceous plant or a narcissus. CONSTITUTION:The bulb of cluster-amaryllis of amaryllidaceous plant or a narcissus is ground, water is added to the ground matter of the bulb which is heated at 55-60 deg.C for 18hr, and extracted. The prepared solution is filtered to give an extracted solution, which is blended with a cosmetic base to give a cosmetic, e.g., a skin cosmetic, hair cosmetic, etc. The amount of the extracted solution used is not particularly limited, and the extracted solution may be blended with other extracted solution of a crude drug. The cosmetic is transmitted through the skin and absorbed in the tissue to enlarge the affected peeipheral blood, to improve blood stream, to activate intermediate metabolism, to promote the supply of nutrition and the excretion of effete matter, and to make the color of the skin better. It prevents the aging of the skin and the occurrence of the stain caused by the influence of the sunlight, and exhibits beautifying action.
Sodium Oxybate Oral Solution may impair respiratory drive, especially in patients with compromised respiratory function. In overdoses, life-threatening respiratory depression has been reported [see Overdosage (10)].

In an adult study assessing the respiratory-depressant effects of Sodium Oxybate Oral Solution at doses up to 9 g per night in 21 patients with narcolepsy, no dose-related changes in oxygen saturation were demonstrated in the group as a whole. One of the four patients with preexisting, moderate-to-severe sleep apnea had significant worsening of the apnea/hypopnea index during treatment.

In an adult study assessing the effects of Sodium Oxybate Oral Solution 9 g per night in 50 patients with obstructive sleep apnea, Sodium Oxybate Oral Solution did not increase the severity of sleep-disordered breathing and did not adversely affect the average duration and severity of oxygen desaturation overall. However, there was a significant increase in the number of central apneas in patients taking Sodium Oxybate Oral Solution, and clinically significant oxygen desaturation (≤55%) was measured in three patients (6%) after Sodium Oxybate Oral Solution administration, with one patient withdrawing from the study and two continuing after single brief instances of desaturation.

During polysomnographic evaluation (PSG), central sleep apnea and oxygen desaturation were observed in pediatric patients with narcolepsy treated with Sodium Oxybate Oral Solution.

Prescribers should be aware that increased central apneas and clinically relevant desaturation events have been observed with Sodium Oxybate Oral Solution administration in adult and pediatric patients.

In adult clinical trials in 128 patients with narcolepsy, two subjects had profound CNS depression, which resolved after supportive respiratory intervention. Two other patients discontinued sodium oxybate because of severe difficulty breathing and an increase in obstructive sleep apnea. In two controlled trials assessing PSG measures in adult patients with narcolepsy, 40 of 477 patients were included with a baseline apnea/hypopnea index of 16 to 67 events per hour, indicative of mild to severe sleep-disordered breathing. None of the 40 patients had a clinically significant worsening of respiratory function as measured by apnea/hypopnea index and pulse oximetry at doses of 4.5 g to 9 g per night.

Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients, in men, in postmenopausal women not on hormone replacement therapy and among patients with narcolepsy.
Patients diagnosed with odontogenic cysts are included in this study. Cone Beam Computed Tomography (CBCT) and Intraoral Scans are performed and registered in a software for the design of Patient Specific Implants (PSI). A customized implant is designed and manufactured using Selective Laser Melting (SLM). Under local anesthesia, cystostomy is performed, and the wall of the cyst is sampled for histological diagnosis. The PSI is anchored subperiosteally on the bone using osteosynthesis screws. After a 6-month-long decompression period a CBCT scan is performed to determine whether enucleation of the cyst is feasible. Enucleation of the cyst is performed and the remaining cyst lining is sent for histopathological examination.
The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
This multicenter study will be conducted in 2 parts (Part 1 and 2). This is an ascending multiple oral dose, open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia. In part 1, subjects will have up to two visits, including a screening visit, and a 17-day in-clinic period. Eligible subjects will be admitted to the clinic on Day -4 to start or complete a taper/washout of their prior antipsychotic medication(s) under the supervision of the Investigator. On Day 1, after subjects have successfully completed the taper/washout of prior medication, subjects will be administered SEP 363856, and dosing with SEP 363856 will continue once-daily for 10 days in-clinic dosing. From Day 11 through Day 13, inclusive, subjects will be restabilized on their adequate antipsychotic medication(s) before clinic discharge on Day 14. Some subjects may require a longer restabilization process based on Investigator judgment. Subjects who discontinue the study prior to Day 13 will require an in-clinic stay for 3 days (or longer based on Investigator judgment) for restabilization on prior medications. In Part 2, Subjects will have up to two visits, including a screening visit, and a 21-day in-clinic period. Eligible subjects will be admitted to the clinic on Day -4 to start or complete a taper/washout of their prior antipsychotic medication(s) under the supervision of the Investigator. On Day 1, after subjects have successfully completed the taper/washout of prior medication, subjects will be administered SEP 363856, and dosing with SEP 363856 will continue once-daily for 14 days in-clinic dosing. From Day 15 through Day 17, inclusive, subjects will be restabilized on their adequate antipsychotic medication(s) before clinic discharge on Day 18. Some subjects may require a longer restabilization process based on Investigator judgment. Subjects who discontinue the study by Day 17 will require an in-clinic stay for 3 days (or longer based on Investigator judgment) for restabilization on prior medications.
Keratinous fibres, esp. human hair, are dyed by applying in either order:-   (a) a composition comprising an oxidation base and iodide ions, and optionally 5,6 - dihydroxyindole, but preferably no further reactant (coupler); and   (b) a composition comprising hydrogen peroxide. The oxidation base may be of the o- or p-phenylenediamine, o- or p- aminophenol, N,N'-diphenylalkylenediamine or heterocyclic series. The iodide ions may be provided by an alkali metal, alkaline earth metal or ammonium iodide. Multicompartment kits for the compositions are disclosed. Advantages of the process include, rapid wash - and light - fast colorations without the need for alkalinising agents. <IMAGE>
The invention provides the preparation method and Gynura procumbens (Lour.) Merr sugar-free buccal tablet of a kind of Gynura procumbens (Lour.) Merr extract, the preparation method of Gynura procumbens (Lour.) Merr extract is comprised the following steps：Gynura procumbens (Lour.) Merr is extracted with water, Gynura procumbens (Lour.) Merr extract is obtained；The temperature of the extraction is 60 DEG C~75 DEG C；The time of the extraction is 2~9 hours；The pressure of the extraction is 18Pa~22Pa.Gynura procumbens (Lour.) Merr extract prepared by above-mentioned preparation method is had preferable anti-bacteria and anti-virus performance by the present invention with reference to the Gynura procumbens (Lour.) Merr sugar-free buccal tablet that pharmaceutically acceptable auxiliary material is obtained, and so as to reach throat-clearing throat-moistening, treats the effect of mouth disease.Test result indicate that：The Gynura procumbens (Lour.) Merr sugar-free buccal tablet that the present invention is provided is test object with 30 abscess of throat patients, and its effective percentage may be up to 93.3%.
Critical illness is associated with increased bone turnover, loss of bone density, and increased risk of fragility fractures. The impact of bone antiresorptive agents in this population is not established. This trial examined the efficacy, feasibility, and safety of antiresorptive agents administered to critically ill women aged fifty years or greater. Women aged 50 years or greater admitted to an intensive care unit for at least 24 h were randomised to receive an antiresorptive agent (zoledronic acid or denosumab) or placebo, during critical illness and six months later (denosumab only). Bone turnover markers and bone mineral density (BMD) were monitored for 1 year. We studied 18 patients over 35 months before stopping the study due to the COVID-19 pandemic. Antiresorptive medications decreased the bone turnover marker type 1 cross-linked c-telopeptide (CTX) from day 0 to 28 by 43% (± 40%), compared to an increase of 26% (± 55%) observed with placebo (absolute difference - 69%, 95% CI - 127% to - 11%), p = 0.03). Mixed linear modelling revealed differences in the month after trial drug administration between the groups in serum CTX, alkaline phosphatase, parathyroid hormone, and phosphate. Change in BMD between antiresorptive and placebo groups was not statistically analysed due to small numbers. No serious adverse events were recorded. In critically ill women aged 50-years and over, antiresorptive agents suppressed bone resorption markers without serious adverse events. However, recruitment was slow. Further phase 2 trials examining the efficacy of these agents are warranted and should address barriers to enrolment.Trial registration: ACTRN12617000545369, registered 18th April 2017.
The present invention includes a processing portion, a plurality of medicine chests, a medical order database, an image capture device, a medicine image database, and an image recognition training module. The plurality of medicine chests are respectively placed with medicine and respectively connected to the processing portion. The medical order database is provided with a plurality of medical order codes. The image recognition training module may obtain the medicine images from different angles of medicine in advance and store the images into the medicine image database with corresponding medicine codes. When corresponding medical order code is input to the processing portion, the processing portion controls the corresponding medicine chest to open and take out medicine and the image capture device captures the image of medicine, so that the medicine may be picked up after double checking of medicine images and medical order codes. Thus, the present invention utilizes the image recognition training module to enhance the recognition accuracy, reduce the probability of false judgment by human eyes through image recognition for medicine picking, increase the accuracy of medicine picking after double checking through medical order database, and manually check again to successfully complete the medicine picking operation.
PURPOSE: Women with symptomatic pelvic organ prolapse are facing the choice between several treatment options and a potentially difficult decision. The aim of this study was to examine the effect of decisional conflict, patient characteristics and other decision-related factors on treatment decision in women with pelvic organ prolapse.
METHODS: Data from the SHADE-POP trial were used. Women with symptomatic pelvic organ prolapse who visited their gynaecologist for (new) treatment options were included. In all participants, demographical characteristics and validated questionnaires concerning decisional conflict (DCS), shared decision making (SDM-Q-9), information provision (SCIP-B), anxiety and depression (HADS) and satisfaction with care (PSQ-18) were collected 2 weeks after the visit. Analyses were performed using univariate and multivariate linear and logistic regression analyses.
RESULTS: Ninety six women with pelvic organ prolapse facing a treatment decision were included. An increase in decisional conflict as experienced by patients was related to the choice of more conservative treatment, such as pelvic floor muscle training or pessary, instead of surgery (p = 0.02). Shared decision making, better information provision and satisfaction with care were related to lower levels of decisional conflict (p = 0.001).
CONCLUSION: Decisional conflict in women with pelvic organ prolapse favours conservative treatment instead of surgery. Gaining knowledge on the effect of decisional conflict, patient characteristics and other decision-related factors on treatment decision in pelvic organ prolapse will be a step towards a better-guided treatment decision and better patient-reported outcomes for this group of patients. NL 55737.028.15, 30-10-2016.
Despite the success of antiretroviral therapy (ART), a subset of HIV-1-infected patients have uncontrolled viremia, multiple drug class resistance, and limited treatment options. Tenofovir disoproxil fumarate (TDF) forms part of most ART regimens, however its long-term use is associated with renal tubulopathy and reduced bone mineral density. Viral mutations (eg, K65R, multiple thymidine analog mutations (TAMs) can confer resistance or reduced susceptibility to TDF.

Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. When compared to TDF, TAF demonstrated lower plasma tenofovir concentrations and more potent antiviral activity at approximately one-tenth of the dose. TAF has the advantage of reduced tenofovir exposure to the renal tubules and bone, potentially resulting in fewer kidney and bone effects. As with TDF, TAF has potent activities against hepatitis B virus (HBV), and may be a treatment option for patients with HIV/HBV co-infections. Phase 2 trials have demonstrated the non-inferiority of TAF to TDF in treating HIV-1 infection in ART-naive patients. Smaller reductions in bone mineral density were measured with TAF than TDF. The most common adverse events were nausea and diarrhea.

This single-arm, single-site, open-label trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure. The study will recruit patients who have failed TDF-containing regimens or cannot take TDF (due to resistance mutations or risk of renal injury) and for whom abacavir/lamivudine (ABC/3TC) is not an optimal alternative. Eligible patients will begin 9 days of inpatient directly observed therapy (DOT) with F/TAF plus their pre-enrollment background regimen. On Day 10, patients will switch to F/TAF plus OBT while waiting for the results of Day 10 HIV RNA results. Patients with an HIV RNA decline of \<0.5 log10 from Day 1 to Day 10 will discontinue F/TAF, end their study participation, and continue OBT (with TDF/FTC or ABC/3TC in place of F/TAF, as appropriate) under the 14-I-0009 protocol. Patients with a greater than or equal to 0.5 log10 decline in HIV RNA will continue on F/TAF + OBT for 48 weeks, with periodic outpatient assessments of adherence, safety, renal function, bone mineral density, HIV RNA, and CD4 T cell counts. Switching of one or more drugs in an ART regimen due to inadequate viral response will require inpatient DOT under 14-I-0009.
This information management device (10) has a person specifying unit (110), a tracking information generating unit (111), a label information generating unit (112), a determination unit (113) and an output unit (114). The person specifying unit (110) generates person-specifying information which identifiably specifies each of multiple persons present in a predefined area. The tracking information generating unit (111) tracks the position of a person over time and generates tracking information. The label information generating unit (112) attaches a prescribed label to the information about multiple persons included in the person-specifying information and generates label information. The determination unit (113) determines whether or not a person has had close contact with an infected person on the basis of the tracking information and the label information. The output unit (114) outputs the results of the determination.
<P>PROBLEM TO BE SOLVED: To provide a new crystal form (β-crystal form) of ivabradine hydrochloride, a method for producing the crystal form, and a medicinal composition containing the crystal form.  <P>SOLUTION: A mixture of the ivabradine hydrochloride represented by chemical formula (1) and water, or a mixture of the ivabradine hydrochloride, isopropanol and water is heated until the dissolution is completed. The obtained solution is gradually cooled until the crystallization is completed, and the formed crystal is collected. The obtained crystal gives a peculiar characteristic powder X-ray diffraction spectrum. The medicine containing the crystal is used as a bradycardic agent, an antianginal agent, an agent against myocardial infarction, an agent against cardiac failure or the like.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.